| Document |
Document Title |
|
WO/2022/061224A1 |
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic an...
|
|
WO/2022/052923A1 |
Provided are a dihydropyrimidine compound as shown in formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof, and an application thereof. The dihydropyrimidine compound has good anti-HBV activity, and can be used ...
|
|
WO/2022/056042A1 |
The present disclosure provides SPNS2 inhibitor compounds according to Formula (I) and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical composition...
|
|
WO/2022/056068A1 |
The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myoca...
|
|
WO/2022/053541A1 |
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
|
|
WO/2022/055926A1 |
The present disclosure relates to compounds that increase sarcospan expression. The disclosure further relates to methods of treating a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need the...
|
|
WO/2022/053803A1 |
The present invention relates to the use of compounds of Formula (I) as agrochemicals, preferably herbicides, wherein X, X', X'', R2, F3, R4 and R5 are as defined herein. The invention further relates to agrochemical compositions compris...
|
|
WO/2022/053823A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein m, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceuti...
|
|
WO/2022/055321A1 |
The present invention provides: a compound for a capping layer, represented by formula 1; and an organic light-emitting device including a first electrode, a second electrode, at least a single organic material layer interposed between t...
|
|
WO/2022/049376A1 |
The invention relates to compounds of formula (I): and related aspects.
|
|
WO/2022/051596A1 |
The present disclosure relates to compounds of Formula (I') and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/049011A1 |
The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R7 are as described herein: (I) Further provided are pharmaceutical compositions includ...
|
|
WO/2022/049134A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein B, C, L, X, Y, RL and R3 to R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2022/048988A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, useful as plant growth regulators and/or seed germination promoters.
|
|
WO/2022/049253A1 |
Substituted N-heteroaryl-N-pyridinylacetamide of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds...
|
|
WO/2022/048533A1 |
Provided are a series of five-membered heteroaryl compounds and the use thereof, and specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein the compound can be used to ...
|
|
WO/2022/049496A1 |
The present invention relates to a novel compound having a selective HDAC6 inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof in preparation of a therapeutic medicament, a pharmaceutical ...
|
|
WO/2022/049602A1 |
The present invention relates to non-granulated compositions comprising rivaroxaban for oral administration, wherein rivaroxaban is at a concentration of not more than 20% by weight of the composition. The said non-granulated composition...
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/043374A1 |
The present invention relates to compounds of formula (II) wherein R1-R5, X and L are as described herein, and pharmaceutically acceptable salts thereof, compositions including the compounds and methods of using the compounds, particular...
|
|
WO/2022/042712A1 |
The present invention relates to a salt of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-me
thyl-1H-indol-2-yl)(3,3-difluoroazetidine-1-yl)methanone (hereinafter referred to as "compound A"), a solid form of the salt, a metho...
|
|
WO/2022/042591A1 |
Provided is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The c...
|
|
WO/2022/042613A1 |
Disclosed are a 1H-pyrazol-4-amide derivative having a structure as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, the use thereof as an inhibitor for FGFR and a mutation thereof,...
|
|
WO/2022/046861A1 |
Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disea...
|
|
WO/2022/046606A1 |
The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2022/042691A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/047230A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases as...
|
|
WO/2022/044024A1 |
Compounds usable as substrate-competitive inhibitors of GSK-3, and uses thereof in modulating (e.g., inhibiting) GSK-3 activity and in treating biological conditions associated with GSK-3, are provided. The compounds can be collectively ...
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/038116A1 |
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of a disorder selected from autoimmune disorders, mental disorders, neurodegenerative disorders, pain, respiratory diseases...
|
|
WO/2022/038356A1 |
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...
|
|
WO/2022/040324A1 |
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).
|
|
WO/2022/038299A1 |
The present invention provides a novel group of active compounds based on the psychoactive compound psilocin. The psilocin derivatives provided herein exhibit improved pharmacokinetic properties during uptake as compared to psilocin, as ...
|
|
WO/2022/037691A1 |
Provided are an aromatic ring-lactam compound as shown in formula (I), and a preparation method therefor and the use thereof. The aromatic ring-lactam compound has a novel structure, has good inhibitory activity on ERK1/2 kinases, can in...
|
|
WO/2022/033532A1 |
Provided are an FGFR and a mutation inhibitor thereof, and a preparation method therefor and the use thereof. In particular, provided are an FGFR having a structure of formula (I) and a mutation inhibitor thereof, a preparation method th...
|
|
WO/2022/033420A1 |
The present invention provides a compound as a PAK4 inhibitor having a structure shown in formula I, or a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, or a pharmaceutically acceptable hydrate, solvate, or s...
|
|
WO/2022/034203A1 |
The present invention provides, inter alia, a process for producing a compound of formula (I) wherein the substituents are as defined in claim 1. The present invention further provides intermediate compounds utilised in said process, and...
|
|
WO/2022/033567A1 |
The present disclosure relates to benzimidazole derivatives, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a benzimidazole derivative represented by the general formula (I), a pr...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/035805A1 |
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure...
|
|
WO/2022/036188A1 |
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be u...
|
|
WO/2022/034568A1 |
This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysop...
|
|
WO/2022/031939A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer.
|
|
WO/2022/032068A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...
|
|
WO/2022/028154A1 |
An N-carboxamidopyrazoline derivative, provided with the compound of formula (I) or an enantiomer, a diastereomer, an epimer, and a racemate of same, or a pharmaceutically acceptable salt thereof. The compound is an antagonist of ligand-...
|
|
WO/2022/028421A1 |
Provided by the present invention are a fluorescent traceable amino acid derivative, a preparation method therefor, and an application thereof, belonging to the technical field of biomedicine. The amino acid derivative provided by the pr...
|
|
WO/2022/029041A1 |
Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, n...
|
|
WO/2022/032019A1 |
Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds o...
|
|
WO/2022/029170A1 |
The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the α5 subunit, useful in treating central nervous system diseases and other diseases. In a...
|
|
WO/2022/032144A1 |
Provided herein are compounds that modulate PRTM5 activity. The compounds may inhibit the binding PRMT5 with a PRMT5 substrate adaptor. The compounds can modulate PRMT5 methyltransferase activity, modulate transcription of a gene regulat...
|
